Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
2.645 USD 0.06 ( 2.12%)
Last update at 2026-11-20T21:00:00Z
VOLUME
23759
Market Cap
3.12M

Momentum Score

…

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.63
Low
2.76
High
52 Week Price Range
0.04
Low
311.68
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
2.59
Dividend Yield
-
Revenue TTM
1.14M
Revenue Per Share
1.67
Gross Profit TTM
0.25M
Debt / Equity
0.04
ROE
-27.49%
Net Debt
-27.06M
ROCE
-23.43%
Diluted EPS TTM
-648.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Income before tax -6.07M -3.30M -3.10M -5.93M -5.41M
Net income -6.21M -3.30M -3.10M -5.93M -5.74M
Selling general administrative 7.13M 2.76M 2.64M 5.65M 5.52M
Selling and marketing expenses - 0.29M 0.43M 0.39M 0.92M
Gross profit 0.18M 0.37M 0.55M 0.43M 1.25M
Reconciled depreciation 0.14M 0.08M 0.20M 0.25M 0.32M
Ebit -7.12M -2.66M -2.55M -5.61M -5.19M
Ebitda -6.98M -2.57M -2.35M -5.36M -4.87M
Depreciation and amortization 0.14M 0.08M 0.20M 0.25M 0.32M
Operating income -7.12M -2.68M -2.52M -5.61M -5.19M
Other operating expenses 8.20M 4.42M 4.44M 7.58M 7.79M
Interest expense 0.06M 0.65M 0.54M - 0.22M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.33M
Net interest income -0.06M -0.65M -0.54M -0.48M -0.04M
Income tax expense 0.13M - 0.00M 0.48M 0.33M
Total revenue 1.07M 1.74M 1.93M 1.97M 2.60M
Total operating expenses 7.31M 3.05M 3.07M 6.03M 6.44M
Cost of revenue 0.89M 1.37M 1.37M 1.55M 1.35M
Total other income expense net 1.05M -0.62M -0.58M 0.15M -0.22M
Net income from continuing ops -6.21M -3.30M -3.10M -5.93M -5.74M
Net income applicable to common shares - - - - -5.74M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total assets 34.75M 21.66M 23.13M 29.55M 33.55M
Intangible assets 0.01M 0.01M 0.02M 0.03M 0.04M
Other current assets 0.14M 0.47M 0.01M 0.05M 0.29M
Total liab 5.05M 6.22M 9.20M 14.86M 17.12M
Total stockholder equity 29.71M 15.44M 13.93M 14.69M 16.42M
Other current liab 3.32M 2.99M 4.03M 9.56M 13.52M
Common stock 64.13M 44.53M 4.35M 0.91M 0.16M
Capital stock 64.13M 44.53M 4.35M 0.91M 0.16M
Retained earnings -34.22M -28.02M -24.71M -21.61M -15.69M
Other assets - - - - 9.46M
Cash 28.18M 18.10M 12.07M 17.37M 15.52M
Total current liabilities 4.35M 6.01M 8.90M 14.50M 17.12M
Current deferred revenue 0.10M 0.06M 0.19M 0.17M 0.08M
Net debt -27.06M -17.12M -9.42M -13.61M -13.48M
Short term debt 0.42M 0.77M 2.35M 3.39M 2.05M
Short long term debt 0.36M 0.71M 2.29M 3.33M 2.05M
Short long term debt total 1.12M 0.98M 2.65M 3.76M 2.05M
Other stockholder equity - -0.00M 35.32M 35.59M 30.99M
Property plant equipment - - - - 1.59M
Total current assets 34.51M 21.30M 14.23M 19.52M 22.45M
Net tangible assets - - - - 16.39M
Short term investments - 0.14M - - -
Net receivables 3.23M 1.90M 1.35M 1.58M 5.53M
Long term debt 0.64M 0.10M 0.12M 0.12M -
Inventory 2.96M 0.83M 0.81M 0.53M 1.02M
Accounts payable 0.50M 1.16M 1.28M 1.38M 1.48M
Accumulated other comprehensive income -0.20M -1.08M -1.03M -0.20M 0.96M
Non currrent assets other - - 8.31M 8.74M 9.46M
Non current assets total 0.24M 0.37M 8.89M 10.03M 11.09M
Capital lease obligations 0.12M 0.18M 0.24M 0.31M -
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Investments - 0.06M 0.03M -0.01M -0.05M
Change to liabilities - - - - -0.02M
Total cashflows from investing activities -1.25M 0.06M 0.03M - -0.05M
Net borrowings 0.14M -0.07M 1.42M - -1.04M
Total cash from financing activities 14.43M 8.40M -2.62M 2.94M 1.60M
Change to operating activities - - - - 0.83M
Net income -6.21M -3.30M -3.10M -5.93M -5.74M
Change in cash 10.05M 6.05M -5.29M 1.80M 2.21M
Begin period cash flow 18.13M 12.08M 17.37M 15.57M 13.36M
End period cash flow 28.18M 18.13M 12.08M 17.37M 15.57M
Total cash from operating activities -4.02M -2.35M -1.93M -0.08M 0.27M
Issuance of capital stock 14.29M 2.76M 0.00M 2.19M 3.12M
Depreciation 0.14M 0.08M 0.20M 0.25M 0.32M
Other cashflows from investing activities - 0.07M 0.03M - 0.02M
Change to inventory -0.51M -0.01M -0.19M 0.41M -0.18M
Change to account receivables -1.32M -0.48M -0.32M 0.91M 0.83M
Other cashflows from financing activities - 5.70M -3.93M 0.77M -1.49M
Change to netincome - - - - 3.75M
Capital expenditures 0.00M 0.00M 0.01M 0.07M 0.06M
Change in working capital -2.39M -0.97M -0.38M 1.42M 1.90M
Stock based compensation 5.31M 0.00M 0.35M 0.55M 2.33M
Other non cash items 4.43M 1.85M 1.00M 0.41M 1.12M
Free cash flow -4.02M -2.35M -1.94M -0.15M 0.21M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SXTC
China SXT Pharmaceuticals Inc
0.06
2.12%
2.65 - - 2.74 0.12 43.06 7.08
MKKGY
Merck KGaA ADR
-0.68
2.09%
31.83 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien
-
-%
163.45 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR
0.38
1.77%
21.79 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.
-
-%
43.05 - 10.66 0.01 1.16 2.94 23.11

Profile*

China SXT Pharmaceuticals Inc

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.

178 Taidong Road North, Taizhou, China, 225300

86 523 8629 8290

56

Name Title Year Born
Mr. Feng Zhou Chairman & CEO 1992
Mr. Xiaodong Pan Chief Financial Officer 1978
Mr. Jun Zheng Exec. Director 1978
Mr. Feng Zhou Chairman of the Board & CEO 1992
Mr. Jun Zheng Executive Director 1978
Mr. Feng Zhou Chairman of the Board & Co-CEO 1992
Mr. Sze Beng Lim Co-Chief Executive Officer 1977
Mr. Xiaodong Pan Chief Financial Officer 1977
Mr. Jun Zheng Executive Director 1976

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…